Speech-Language Pathologists in Edgewood, NM Accepting Medicare

8 Speech-Language Pathologists found. Showing 1 - 8

Eva Mae Blakely, MS/CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1090 Mountain Valley Rd, Edgewood, NM 87015 Phone: 505-281-1811    Fax: 505-281-7704

Jessica Besteman Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1090 Mountain Valley Rd, Edgewood, NM 87015 Phone: 505-281-8111

Ms. Ruth Pauline Dismuke Blakely, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1090 Mountain Valley Rd, Edgewood, NM 87015 Phone: 505-281-1811    Fax: 505-281-7704

Mrs. Jeana Spindle, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 27 Camino Estribor, Edgewood, NM 87015 Phone: 505-238-8811    Fax: 505-286-1207

Meghan Voigt, MS, CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 1090 Mountain Valley Road, Edgewood, NM 87015 Phone: 505-281-1811

Mrs. Neita Anne Miller, MS/CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1090 Mountain Valley Rd, Edgewood, NM 87015 Phone: 505-281-1811    Fax: 505-281-7704

Laurel Lynn Elrick, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1090 Mountain Valley Rd, Edgewood, NM 87015 Phone: 505-281-1811

Therapy Partnerships, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 27 Vista Dr, Edgewood, NM 87015 Phone: 505-720-4564

News Archive

The FRS Company receives $23.1M in financing round led by Oak Investment Partners

The FRS Company, a developer and distributor of FRS® Healthy Energy® products, announced today that it has received $23.1 million in its latest financing round led by Oak Investment Partners, LLC. Oak Investment Partners was an early investor in The FRS Company, and its continued support of FRS validates the company's aggressive business strategy for national and international expansion and explosive sales growth.

Catasys' total revenues increase 169% to $2.0 million in 2014

Catasys, Inc., provider of proprietary health management services to health insurers and employers, today reported full year 2014 financial results for the period ended December 31, 2014.

Researchers describe how PDNF protein prolongs the life of T. cruzi parasite

The parasite Trypanosoma cruzi (or T. cruzi), which causes Chagas' disease, will go to great lengths to evade death once it has infected human host cells, researchers have discovered. In a study published in the November 17 online issue of Science Signaling, the researchers describe how a protein called parasite-derived neurotrophic factor (PDNF) prolongs the life of the T. cruzi parasite by activating anti-apoptotic (or anti-cell-death) molecules in the host cell. These protective mechanisms help to explain how host cells continue to survive despite being exploited by T. cruzi parasites.

Study reveals inequities in access to primary care among Canadian prescription opioids users

Stigma and high care needs can present barriers to the provision of high-quality primary care for people with opioid use disorder (OUD) and those prescribed opioids for chronic pain.

Experimental therapy uses immune system to boost cure rate in neuroblastoma

A multicenter research team has announced encouraging results for an experimental therapy using elements of the body's immune system to improve cure rates for children with neuroblastoma, a challenging cancer of the nervous system.

Read more Medical News

› Verified 9 days ago